EXELIXIS, INC. (EXEL): what the price requires

At today's price, EXELIXIS, INC. (EXEL) is priced for +3.4% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.

Generated: 2026-07-19 · Source: https://boothcheck.com/report/EXEL

Headline

FieldValue
TickerEXEL
CompanyEXELIXIS, INC.
Current price$55.97/sh

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin needed6.2%
Operating margin today38.1%
Margin compression implied-31.9pp
Implied growth3.4%
Multiple paid15x operating income

The operating-margin requirement is derived from the framework's value band at year 5, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 8.6% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~5.4pp.

How unusual the bet is: within-range (limited comparison data)

ReferenceValue
vs own history-0.31σ
implied end-window share0%

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset1.66x5expensive
Earnings1.71x5expensive
Relative0.84x5justifies
Growth0.93x3justifies

Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.1%); the inversion above states its own rate.

Per-Model Detail (n=18)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$69.710.80xyesFCF base $0.9B, growth 4% (input: historical growth), terminal g 3.9%, WACC 9.1%, 5yr projection
DCF Exit MultipleGrowth$60.300.93xyesExit EV/EBITDA: 14.1x / 16.1x / 18.1x (bear / base = today's held flat / bull), 5yr
Relative ValuationRelative$66.690.84xyesP/E 24x (static sector reference · 2026-04), scenarios: 20.1x / 24.0x / 27.9x (bear / base = reference held flat / bull), EV/EBITDA 16x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$33.701.66xyesBV/sh $7.24, ROE (TTM) 43.1%, ke 9.3%
Two-Stage Excess ReturnAsset$83.030.67xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$44.501.26xyesRev $2.4B, growth 4% (input: historical growth; tapered), Terminal P/S: 5.3x / 6.3x / 7.3x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair ValueRelative$105.700.53xyesEPS $3.02, growth 35% (input: historical EPS growth), PEG=0.51 (Undervalued)
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$16.603.37xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.50B × (1−21%) / WACC 9.1% → EPV (no growth)
Residual IncomeAsset$53.781.04xyesBV $7.24 + 5yr PV of (ROE (TTM) 43.1% − Kₑ 9.3%) × BV; BV grows 8.8%/yr
Graham NumberAsset$22.182.52xyes√(22.5 × EPS $3.02 × BVPS $7.24) — Graham's conservative floor
EV/EBITDA RelativeRelative$55.621.01xyesEBITDA $0.94B × sector EV/EBITDA 16.0x
FCF YieldEarnings$36.251.54xyesFCF $917.7M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$31.561.77xyesSBC-adj FCF $0.80B (FCF $0.92B − SBC $0.12B) capitalized at Kₑ
Ben Graham FormulaEarnings$97.450.57xyesEPS $3.02 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/BAsset$7.307.67xyesBV $7.24 × (ROIC 9.2% / WACC 9.1%)
P/Sales SectorRelative$35.551.57xyesRevenue $2.38B × sector P/S 4.0x
PEG Fair ValueRelative$113.250.49xyesEPS $3.02 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings YieldEarnings$32.651.71xyesEPS $3.02 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Solvency

FieldValue
Net cash$777.2m
Net debt / NOPAT (after-tax)-1.11x (net cash)
Net debt / operating income (pre-tax)-0.87x (net cash)
Share count CAGR (buyback)-4.6%
Burning cashno

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

Bull Case

Exelixis has the one thing most biotechs never reach: a moat made of cash flow. The cabozantinib franchise is a durable oncology product that produced $555 million in net product revenue in the first quarter alone, with the flagship CABOMETYX growing 8% year over year and recording the company's highest-ever new patient starts. On top of U.S. sales, Exelixis collects royalties from partners abroad, earning "$179.2 million, $166.9 million and $148.5 million, respectively, of royalties on net sales of cabozantinib products outside of the U.S." across the last three years, a stream that grows without the company bearing the commercial cost. That combination produces something rare in the sector: a roughly 39% operating margin, a 43% return on equity, and real free cash flow approaching $900 million.

The balance sheet turns that profitability into optionality. Exelixis carries no debt and roughly $777 million of net cash, and it has been retiring shares at about 4.6% a year. A profitable biotech with net cash can fund its own pipeline, buy back stock, and weather a clinical setback without dilution, which is the opposite of the going-concern math that governs most drug developers. The cash flow models that look at trailing earnings actually understate this kind of business, because they cannot price a pipeline with binary outcomes; the asset and earnings methods read the stock as expensive precisely because they capitalize today's profit and ignore what a new approval could add.

The pipeline is where the next leg has to come from, and it is advancing. Zanzalintinib, the company's next-generation tyrosine kinase inhibitor, is in late-stage development, with regulatory review of the colorectal-cancer combination on track toward a December decision and further trials reading out. The filing details a broad program, including "STELLAR-303 is a phase 3 pivotal t"rial, and maps out the competitive landscape Exelixis expects to enter. The bull case is that the cabozantinib cash machine funds a zanzalintinib franchise that extends the company's oncology position into new tumor types, with the balance sheet absorbing the risk of the bets that do not work.

Bear Case

The disruption risk for Exelixis is concrete and named: generic competition to its single major product. Nearly all of the company's revenue traces to cabozantinib, and the filing is explicit that "The timing of the entrance of generic competitors to CABOMETYX and COMETRIQ" along with legislative and regulatory changes "may further impact the price and reimbursement status of CABOMETYX and COMETRIQ". A one-product company facing a patent cliff is the classic pharmaceutical vulnerability: the day generics arrive, the franchise that funds everything begins to erode, and the timing of that entry is partly outside the company's control. The market is paying for the cabozantinib cash flow to persist long enough, and undisturbed enough, for the pipeline to take over.

The pipeline that is supposed to take over carries its own competitive and clinical risk, which the most recent data sharpened. Zanzalintinib's pivotal colorectal-cancer readout, STELLAR-303, showed an overall-survival trend favoring the combination but one that was not statistically significant across the full study, with the benefit concentrated in patients without active liver metastases, where median survival ran 15.9 months versus 12.7 for the comparator. A subgroup signal is not the same as a clean win, and it complicates the path to broad use. The filing also lays out the crowded field zanzalintinib must beat, naming likely competition in some indications that includes "Roche's capecitabine + Merck's temozolomide; Novartis' everolimus; Merck's" offerings. Oncology is among the most competitive therapeutic areas, and a next-generation TKI has to demonstrate clear superiority, not just activity, to displace entrenched regimens.

The valuation leaves little room for the pipeline to disappoint. The price implies only about 1.4% operating growth a year, which sounds undemanding, but for a company facing an eventual generic cliff, flat is not the same as safe: it requires the franchise to hold and the pipeline to replace it on time. The asset and earnings methods read the price as expensive, and while those lenses understate a high-return drug company, they also flag that today's profit rests on a product with a finite protected life. The bear case is straightforward: a single-product oncology company priced for continuity, facing a known generic threat and a pipeline whose lead readout was ambiguous, is one disappointing trial or one early generic entry away from a sharp reset, even with the fortress balance sheet underneath.

Valuation

The price embeds an undemanding number that hides a demanding requirement. At roughly 14 times company-wide operating income, the implied operating growth is only about 1.4% a year, which for most companies would read as conservative. For a single-product oncology company facing an eventual patent cliff, though, flat growth is a real assumption: it requires the cabozantinib franchise to hold its revenue and the pipeline to replace the erosion when generics arrive. The methods split the way they do for a profitable, asset-light pharma: the relative-multiple and forward-growth families support the price, while the asset and earnings methods read it as expensive.

That split is informative rather than contradictory. The asset and earnings lenses capitalize today's profit against a thin book value and a five-year average operating income, so they structurally understate a company earning a 43% return on equity with almost no balance-sheet capital, and they cannot price the pipeline optionality at all. The relative lens, comparing Exelixis to a drug-manufacturer cohort that includes Vertex, Jazz, and Alkermes, sees a reasonable earnings multiple for a franchise still growing. The honest read is that the static methods are saying the trailing profit alone does not justify the price, and the growth methods are saying the price is fine if the franchise persists and the pipeline delivers. Both can be true; the gap between them is the value of the pipeline and the durability of cabozantinib.

Solvency is unambiguous and is the floor under the downside. Exelixis carries no debt, roughly $777 million of net cash, and generates strong free cash flow, so even a clinical setback or an early generic entry would not threaten the company's existence. The cash funds the buyback and the pipeline without recourse to capital markets. The price reflects a profitable oncology company whose central question is not survival but succession: whether the cabozantinib cash flow lasts long enough, and the pipeline arrives strong enough, to justify paying today for continuity.

Catalysts

The first quarter of 2026 confirmed the franchise is still growing. Exelixis reported total revenue of about $611 million, including cabozantinib franchise net product revenue of $555 million, with CABOMETYX net product revenue of $552.8 million, up 8% year over year, and the highest new patient starts in the company's history. The company reiterated its full-year 2026 guidance and continued its buyback. The operating story is steady; the catalysts that matter are clinical and regulatory.

The pipeline calendar is the focus. Regulatory review of zanzalintinib plus atezolizumab for later-line colorectal cancer remained on track toward a December decision, with additional data and new trial starts expected through the year. The pivotal STELLAR-303 final analysis was a mixed result: an overall-survival trend favored the zanzalintinib combination but did not reach statistical significance across the full population, with the clearest benefit in patients without active liver metastases, where median survival was 15.9 months against 12.7 for the comparator. Analyst sentiment is constructive but measured, with a median target near $45 and a range from the mid-$30s to $60. The December regulatory decision and subsequent zanzalintinib readouts are the events most likely to move the stock, because they determine whether the pipeline can succeed the cabozantinib franchise the price is counting on.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

STELLAR-303 update, 2025 to 2026 · Q1 2026 results, May 2026 · analyst consensus, 2026

View the full interactive EXEL report on boothcheck